• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

布鲁顿酪氨酸激酶参与固有免疫和适应性免疫。

Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.

作者信息

Brunner C, Müller B, Wirth T

机构信息

Department of Physiological Chemistry, University of Ulm, Albert-Einstein-Allee 11, D-89081 Ulm, Germany.

出版信息

Histol Histopathol. 2005 Jul;20(3):945-55. doi: 10.14670/HH-20.945.

DOI:10.14670/HH-20.945
PMID:15944945
Abstract

Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signalling. Gene targeting experiments revealed that Btk is important for B cell development and function. However, Btk is not only expressed in B cells, but also in most other haematopoietic lineages except for T cells and plasma cells. Recently we found that Btk is involved in Toll-like receptor signalling. Toll-like receptors play an important role in innate immunity. They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens. Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.

摘要

布鲁顿酪氨酸激酶(Btk)是一种细胞质酪氨酸激酶,主要参与B细胞受体信号传导。基因靶向实验表明,Btk对B细胞的发育和功能至关重要。然而,Btk不仅在B细胞中表达,在除T细胞和浆细胞外的大多数其他造血谱系中也有表达。最近我们发现,Btk参与Toll样受体信号传导。Toll样受体在固有免疫中起重要作用。它们在肥大细胞、巨噬细胞和树突状细胞上高度表达,这些细胞对于识别并进而清除微生物病原体至关重要。因此,Btk可能在固有免疫和适应性免疫的免疫活性细胞功能中发挥重要作用。

相似文献

1
Bruton's Tyrosine Kinase is involved in innate and adaptive immunity.布鲁顿酪氨酸激酶参与固有免疫和适应性免疫。
Histol Histopathol. 2005 Jul;20(3):945-55. doi: 10.14670/HH-20.945.
2
Bruton's tyrosine kinase (Btk)-the critical tyrosine kinase in LPS signalling?布鲁顿酪氨酸激酶(Btk)——LPS信号传导中的关键酪氨酸激酶?
Immunol Lett. 2004 Mar 29;92(1-2):15-22. doi: 10.1016/j.imlet.2003.11.017.
3
Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.布鲁顿酪氨酸激酶抑制剂螯合Y551并阻止磷酸化的能力决定了其抑制Fc受体而非B细胞受体信号传导的效力。
Mol Pharmacol. 2017 Mar;91(3):208-219. doi: 10.1124/mol.116.107037. Epub 2017 Jan 6.
4
Bruton's tyrosine kinase is required for apoptotic cell uptake via regulating the phosphorylation and localization of calreticulin.布鲁顿酪氨酸激酶通过调节钙网织蛋白的磷酸化和定位来促进凋亡细胞的摄取。
J Immunol. 2013 May 15;190(10):5207-15. doi: 10.4049/jimmunol.1300057. Epub 2013 Apr 17.
5
Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.B细胞抗原受体介导的布鲁顿酪氨酸激酶激活需要CD19 Y484和Y515的磷酸化以及磷脂酰肌醇3激酶的相关激活。
J Immunol. 1999 Apr 15;162(8):4438-46.
6
The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.布鲁顿酪氨酸激酶在自身免疫中的作用及治疗意义。
Expert Rev Clin Immunol. 2016 Jul;12(7):763-73. doi: 10.1586/1744666X.2016.1152888. Epub 2016 Mar 4.
7
Bruton's tyrosine kinase regulates TLR9 but not TLR7 signaling in human plasmacytoid dendritic cells.布鲁顿酪氨酸激酶调控人浆细胞样树突状细胞中的TLR9信号通路,但不调控TLR7信号通路。
Eur J Immunol. 2014 Apr;44(4):1130-6. doi: 10.1002/eji.201344030. Epub 2014 Jan 20.
8
Bruton's tyrosine kinase is activated upon CD40 stimulation in human B lymphocytes.布鲁顿酪氨酸激酶在人B淋巴细胞受到CD40刺激时被激活。
Immunobiology. 2002 Oct;206(4):432-40. doi: 10.1078/0171-2985-00192.
9
Bruton's tyrosine kinase--an integral protein of B cell development that also has an essential role in the innate immune system.布鲁顿酪氨酸激酶——B 细胞发育的必需蛋白,在固有免疫系统中也具有重要作用。
J Leukoc Biol. 2014 Feb;95(2):243-50. doi: 10.1189/jlb.0513307. Epub 2013 Nov 18.
10
Bruton's tyrosine kinase is dispensable for the Toll-like receptor-mediated activation of mast cells.布鲁顿酪氨酸激酶对于Toll样受体介导的肥大细胞激活是可有可无的。
Cell Signal. 2009 Jan;21(1):79-86. doi: 10.1016/j.cellsig.2008.09.010. Epub 2008 Sep 26.

引用本文的文献

1
Post-marketing surveillance of tirabrutinib in 189 patients with r/r primary central nervous system lymphoma.189例复发/难治性原发性中枢神经系统淋巴瘤患者使用替拉布替尼的上市后监测。
Future Oncol. 2025 Jun;21(15):1837-1847. doi: 10.1080/14796694.2025.2507561. Epub 2025 May 27.
2
Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies.进展性多发性硬化症:评估当前疗法并探索未来治疗策略。
Neurotherapeutics. 2025 Jul;22(4):e00601. doi: 10.1016/j.neurot.2025.e00601. Epub 2025 May 9.
3
Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies.
布鲁顿酪氨酸激酶抑制剂TAS5315在健康志愿者中的药理学与安全性:首次人体、随机、递增剂量研究。
Br J Clin Pharmacol. 2025 Aug;91(8):2340-2351. doi: 10.1002/bcp.70039. Epub 2025 Mar 14.
4
BTK and YKL-40 Levels and Their Association with Acute AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.BTK和YKL-40水平及其与急性水通道蛋白4-IgG阳性视神经脊髓炎谱系障碍的关联。
Mol Neurobiol. 2025 Apr;62(4):4785-4801. doi: 10.1007/s12035-024-04588-5. Epub 2024 Nov 1.
5
Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance.非受体酪氨酸激酶:它们在肿瘤进展和耐药中的结构及机制作用
Cancers (Basel). 2024 Aug 2;16(15):2754. doi: 10.3390/cancers16152754.
6
Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination.布鲁顿酪氨酸激酶在多发性硬化症患者不同类型脑损伤及实验性脱髓鞘中的表达。
Front Immunol. 2023 Nov 13;14:1264128. doi: 10.3389/fimmu.2023.1264128. eCollection 2023.
7
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.在干燥综合征中的疗效和安全性:一项随机、双盲、安慰剂对照的 2 期试验结果。瑞米替尼,一种选择性强效口服 BTK 抑制剂。
Ann Rheum Dis. 2024 Feb 15;83(3):360-371. doi: 10.1136/ard-2023-224691.
8
Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial.在对甲氨蝶呤反应不足的类风湿关节炎患者中,不可逆共价布鲁顿酪氨酸激酶抑制剂 TAS5315 与安慰剂的比较:一项随机、双盲、IIa 期试验。
Ann Rheum Dis. 2023 Aug;82(8):1025-1034. doi: 10.1136/ard-2022-223759. Epub 2023 May 22.
9
Bruton tyrosine kinase inhibitors for multiple sclerosis.用于多发性硬化症的布鲁顿酪氨酸激酶抑制剂。
Nat Rev Neurol. 2023 May;19(5):289-304. doi: 10.1038/s41582-023-00800-7. Epub 2023 Apr 13.
10
Design, synthesis and evaluation of a series of potential prodrugs of a Bruton's tyrosine kinase (BTK) inhibitor.布鲁顿酪氨酸激酶(BTK)抑制剂一系列潜在前药的设计、合成与评价
Front Pharmacol. 2023 Mar 8;14:1162216. doi: 10.3389/fphar.2023.1162216. eCollection 2023.